Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants.

Federico M TorresLidia SerraMarco Aurélio Palazzi Safádi

Published in: Expert review of vaccines (2020)

Robust data support the use of MenACWY-TT in infants starting as early as 6 weeks of age. MenACWY-TT was safe and well tolerated in infants, was immunogenic after priming and booster, and demonstrated persistent immunogenicity. Lower persistence for serogroup A relative to other serogroups based on serum bactericidal assays (SBAs) using human complement appears to be a class effect of MenACWY conjugate vaccines. Correlates of protection other than SBA are being explored, including immunologic responses associated with different carrier proteins.

Keyphrases

endothelial cells
electronic health record
high throughput
big data
machine learning
induced pluripotent stem cells
cancer therapy
gestational age
deep learning